BioStrand Omics Analysis Blog:
AI

A brief retrospective on our second blogiversary

Dr Ingrid Brands, General Manager | September 21, 2022

It’s been an eventful two years, to the month, since we launched our omics and analysis blog. Our...

AI in Biopharma: Challenges and Opportunities

Dr Ingrid Brands, General Manager | September 14, 2022

There are an estimated novemdecillion, or 1060, molecules in the known universe with potential...

Accelerate Biomarker Discovery with Artificial Intelligence

Dr Ingrid Brands, General Manager | August 31, 2022

Biomarkers play a critical role in realizing the true potential of precision medicine. As accurate...

Top 4 challenges of equitable precision medicine

Dr Ingrid Brands, General Manager | August 25, 2022

In our previous articles on precision medicine, we reviewed how advances in precision medicine...

Closing the Gap of Text and the Biosphere with LENSai™ NLP Link

Dr Ingrid Brands, General Manager | August 17, 2022

Bridging the gap between raw sequence data, secondary research, experimental data, and the...

Subscribe to our blog

Explained: A brief look into AlphaFold 2

Sébastien Lemal PhD | August 3, 2022

The year 2021 has been a wild ride for structural biologists, with the advent of AlphaFold2,...

AI-powered genomics to advance precision medicine

Dr Ingrid Brands, General Manager | July 27, 2022

Sir William Osler, often called the father of modern medicine, was among the first to articulate a ...

AI, NLP and the ROI of drug development

Dr Ingrid Brands, General Manager | July 20, 2022

The out-of-pocket R&D costs of developing a single drug, whether successfully launched or not, are...

Accelerating pharma R&D and innovation through technology partnerships

Dr Ingrid Brands, General Manager | July 13, 2022

Biopharmas are increasingly turning to alliances & partnerships to drive external innovation....

Computational Antibody Design: The Future Of Antibody Discovery

Dr Ingrid Brands, General Manager | June 22, 2022

In 2021, the FDA approved the 100th monoclonal antibody product, marking a significant milestone...

Improving Drug Safety with Adverse Event Detection Using NLP

Dr Ingrid Brands, General Manager | June 15, 2022

It is estimated that Adverse Events (AEs) are likely one of the 10 leading causes of death and...